Amphastar Pharmaceuticals reported a net revenue of $95.9 million for Q4 2020, representing a 15% increase compared to the same period in the previous year. However, the company experienced a GAAP net loss of $6.3 million, or $0.13 per share, though adjusted non-GAAP net income was $8.0 million, or $0.16 per share.
Net revenues for the fourth quarter were $95.9 million.
GAAP net loss for the fourth quarter was $6.3 million, or $0.13 per share.
Adjusted non-GAAP net income for the fourth quarter was $8.0 million, or $0.16 per share.
Glucagon's approval and growth in Primatene Mist and epinephrine sales drove top-line growth in 2020.
Amphastar remains optimistic that the trends of growth in Primatene Mist® and epinephrine multi-dose vials sales will continue into 2021 and looks forward to the pipeline’s continued development.
Visualization of income flow from segment revenue to net income
Analyze how earnings announcements historically affect stock price performance